Risankizumab Versus Secukinumab: A Real-World Efficacy and Cost per Responder Comparison in Patients With Psoriasis in Italy
Introduction: Risankizumab and secukinumab are effective treatment options for patients with moderate to severe psoriasis. Objective: We sought to estimate the efficacy and the cost per responder of risankizumab and secukinumab by comparing these two drugs in a real-life setting. Methods:.A mul...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Mattioli1885
2025-01-01
|
| Series: | Dermatology Practical & Conceptual |
| Subjects: | |
| Online Access: | https://dpcj.org/index.php/dpc/article/view/4838 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832540725399519232 |
|---|---|
| author | Federico Pirro Giacomo Caldarola Nicoletta Bernardini Maria Grazia Celeste Annunziata Dattola Eleonora De Luca Marco Galluzzo Domenico Giordano Chiara Izzi Giulia Maretti Lorenzo Marcelli Roberto Ravasio Antonio Giovanni Richetta Nevena Skroza Marina Talamonti Arianna Zangrilli Luca Bianchi Giovanni Pellacani Severino Persechino Concetta Potenza Ketty Peris Clara De Simone |
| author_facet | Federico Pirro Giacomo Caldarola Nicoletta Bernardini Maria Grazia Celeste Annunziata Dattola Eleonora De Luca Marco Galluzzo Domenico Giordano Chiara Izzi Giulia Maretti Lorenzo Marcelli Roberto Ravasio Antonio Giovanni Richetta Nevena Skroza Marina Talamonti Arianna Zangrilli Luca Bianchi Giovanni Pellacani Severino Persechino Concetta Potenza Ketty Peris Clara De Simone |
| author_sort | Federico Pirro |
| collection | DOAJ |
| description |
Introduction: Risankizumab and secukinumab are effective treatment options for patients with moderate to severe psoriasis.
Objective: We sought to estimate the efficacy and the cost per responder of risankizumab and secukinumab by comparing these two drugs in a real-life setting.
Methods:.A multicentric retrospective study was conducted in patients from the Lazio region of Italy affected by moderate-to-severe psoriasis who initiated risankizumab or secukinumab between September 2020 to September 2022. Psoriasis Area and Severity Index (PASI) was measured at baseline and after 16, 52, and 78 weeks. Clinical responses were evaluated by PASI90 and PASI100 responses at the same timepoints. The cost per responder at week 16 and 52 was adopted as a cost-effectiveness indicator.
Results: Included were 141 patients, 74 (52.5%) treated with risankizumab and 67 (47.5%) treated with secukinumab. PASI90 responses in risankizumab-treated patients were higher than those observed in patients treated with secukinumab at both weeks 16 and 52 [79.7% vs 64.2% (p=0.041) and 98.6% vs 83.6% (p=0.003), respectively]. Risankizumab also showed superior PASI100 rates at week 52 (85.5% vs 65.6%, p=0.009). No statistically significant differences were observed in PASI90 and PASI100 rates between the 2 groups at week 78. The cost per PASI90 and PASI100 responder for risankizumab was lower at both weeks 16 (€5833.66 and €8394.78, compared to €8747.18 and €10746.53 for secukinumab) and 52 (€11798.90 and €13598.73 vs €15347.70 and €19568.31, respectively).
Conclusions: Risankizumab showed superior efficacy than secukinumab and a lower cost per responder.
|
| format | Article |
| id | doaj-art-805615727c874ea8bc8e508db2d579a2 |
| institution | Kabale University |
| issn | 2160-9381 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Mattioli1885 |
| record_format | Article |
| series | Dermatology Practical & Conceptual |
| spelling | doaj-art-805615727c874ea8bc8e508db2d579a22025-02-04T15:41:32ZengMattioli1885Dermatology Practical & Conceptual2160-93812025-01-0115110.5826/dpc.1501a4838Risankizumab Versus Secukinumab: A Real-World Efficacy and Cost per Responder Comparison in Patients With Psoriasis in ItalyFederico Pirro0Giacomo Caldarola1Nicoletta Bernardini2Maria Grazia Celeste3Annunziata Dattola4Eleonora De Luca5Marco Galluzzo6Domenico Giordano7Chiara Izzi8Giulia Maretti 9Lorenzo Marcelli10Roberto Ravasio11Antonio Giovanni Richetta12Nevena Skroza13Marina Talamonti14Arianna Zangrilli15Luca Bianchi16Giovanni Pellacani17Severino Persechino18Concetta Potenza19Ketty Peris20Clara De Simone21UOC di Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli - IRCCS, Rome, Italy UOC di Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli - IRCCS, Rome, Italy Dermatology Unit “D. Innocenzi”, Department of Medical and Surgical Sciences and Biotechnologies, Sapienza University of Rome-Polo Pontino, Latina, ItalyHospital Pharmacy, Policlinico Tor Vergata, Rome, ItalyUnit of Dermatology, Department of Internal Medicine and Medical Specialties, Sapienza University, Rome, ItalyUOC di Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli - IRCCS, Rome, Italy Dermatology Unit, Department of Systems Medicine, University of Rome Tor Vergata, Rome, ItalyDepartment of Neurosciences, Mental Health and Sensory Organs, Sapienza University of Roma, Rome, ItalyHospital Pharmacy, Policlinico Tor Vergata, Rome, ItalyDermatology Unit, Department of Clinical Internal, Anesthesiological and Cardiovascular Science, University of La Sapienza, Rome, ItalyDermatology Unit, Department of Systems Medicine, University of Rome Tor Vergata, Rome, ItalyHEOR &RWE Lead, Market Access Provider, Milano, ItalyUnit of Dermatology, Department of Internal Medicine and Medical Specialties, Sapienza University, Rome, ItalyDermatology Unit “D. Innocenzi”, Department of Medical and Surgical Sciences and Biotechnologies, Sapienza University of Rome-Polo Pontino, Latina, ItalyDermatology Unit, Department of Systems Medicine, University of Rome Tor Vergata, Rome, ItalyDermatology Unit, Department of Systems Medicine, University of Rome Tor Vergata, Rome, ItalyDermatology Unit, Department of Systems Medicine, University of Rome Tor Vergata, Rome, ItalyUnit of Dermatology, Department of Internal Medicine and Medical Specialties, Sapienza University, Rome, ItalyDepartment of Neurosciences, Mental Health and Sensory Organs, Sapienza University of Roma, Rome, ItalyDermatology Unit “D. Innocenzi”, Department of Medical and Surgical Sciences and Biotechnologies, Sapienza University of Rome-Polo Pontino, Latina, ItalyUOC di Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli - IRCCS, Rome, Italy UOC di Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli - IRCCS, Rome, Italy Introduction: Risankizumab and secukinumab are effective treatment options for patients with moderate to severe psoriasis. Objective: We sought to estimate the efficacy and the cost per responder of risankizumab and secukinumab by comparing these two drugs in a real-life setting. Methods:.A multicentric retrospective study was conducted in patients from the Lazio region of Italy affected by moderate-to-severe psoriasis who initiated risankizumab or secukinumab between September 2020 to September 2022. Psoriasis Area and Severity Index (PASI) was measured at baseline and after 16, 52, and 78 weeks. Clinical responses were evaluated by PASI90 and PASI100 responses at the same timepoints. The cost per responder at week 16 and 52 was adopted as a cost-effectiveness indicator. Results: Included were 141 patients, 74 (52.5%) treated with risankizumab and 67 (47.5%) treated with secukinumab. PASI90 responses in risankizumab-treated patients were higher than those observed in patients treated with secukinumab at both weeks 16 and 52 [79.7% vs 64.2% (p=0.041) and 98.6% vs 83.6% (p=0.003), respectively]. Risankizumab also showed superior PASI100 rates at week 52 (85.5% vs 65.6%, p=0.009). No statistically significant differences were observed in PASI90 and PASI100 rates between the 2 groups at week 78. The cost per PASI90 and PASI100 responder for risankizumab was lower at both weeks 16 (€5833.66 and €8394.78, compared to €8747.18 and €10746.53 for secukinumab) and 52 (€11798.90 and €13598.73 vs €15347.70 and €19568.31, respectively). Conclusions: Risankizumab showed superior efficacy than secukinumab and a lower cost per responder. https://dpcj.org/index.php/dpc/article/view/4838efficacycost per responderrisankizumabsecukinumabpsoriasis |
| spellingShingle | Federico Pirro Giacomo Caldarola Nicoletta Bernardini Maria Grazia Celeste Annunziata Dattola Eleonora De Luca Marco Galluzzo Domenico Giordano Chiara Izzi Giulia Maretti Lorenzo Marcelli Roberto Ravasio Antonio Giovanni Richetta Nevena Skroza Marina Talamonti Arianna Zangrilli Luca Bianchi Giovanni Pellacani Severino Persechino Concetta Potenza Ketty Peris Clara De Simone Risankizumab Versus Secukinumab: A Real-World Efficacy and Cost per Responder Comparison in Patients With Psoriasis in Italy Dermatology Practical & Conceptual efficacy cost per responder risankizumab secukinumab psoriasis |
| title | Risankizumab Versus Secukinumab: A Real-World Efficacy and Cost per Responder Comparison in Patients With Psoriasis in Italy |
| title_full | Risankizumab Versus Secukinumab: A Real-World Efficacy and Cost per Responder Comparison in Patients With Psoriasis in Italy |
| title_fullStr | Risankizumab Versus Secukinumab: A Real-World Efficacy and Cost per Responder Comparison in Patients With Psoriasis in Italy |
| title_full_unstemmed | Risankizumab Versus Secukinumab: A Real-World Efficacy and Cost per Responder Comparison in Patients With Psoriasis in Italy |
| title_short | Risankizumab Versus Secukinumab: A Real-World Efficacy and Cost per Responder Comparison in Patients With Psoriasis in Italy |
| title_sort | risankizumab versus secukinumab a real world efficacy and cost per responder comparison in patients with psoriasis in italy |
| topic | efficacy cost per responder risankizumab secukinumab psoriasis |
| url | https://dpcj.org/index.php/dpc/article/view/4838 |
| work_keys_str_mv | AT federicopirro risankizumabversussecukinumabarealworldefficacyandcostperrespondercomparisoninpatientswithpsoriasisinitaly AT giacomocaldarola risankizumabversussecukinumabarealworldefficacyandcostperrespondercomparisoninpatientswithpsoriasisinitaly AT nicolettabernardini risankizumabversussecukinumabarealworldefficacyandcostperrespondercomparisoninpatientswithpsoriasisinitaly AT mariagraziaceleste risankizumabversussecukinumabarealworldefficacyandcostperrespondercomparisoninpatientswithpsoriasisinitaly AT annunziatadattola risankizumabversussecukinumabarealworldefficacyandcostperrespondercomparisoninpatientswithpsoriasisinitaly AT eleonoradeluca risankizumabversussecukinumabarealworldefficacyandcostperrespondercomparisoninpatientswithpsoriasisinitaly AT marcogalluzzo risankizumabversussecukinumabarealworldefficacyandcostperrespondercomparisoninpatientswithpsoriasisinitaly AT domenicogiordano risankizumabversussecukinumabarealworldefficacyandcostperrespondercomparisoninpatientswithpsoriasisinitaly AT chiaraizzi risankizumabversussecukinumabarealworldefficacyandcostperrespondercomparisoninpatientswithpsoriasisinitaly AT giuliamaretti risankizumabversussecukinumabarealworldefficacyandcostperrespondercomparisoninpatientswithpsoriasisinitaly AT lorenzomarcelli risankizumabversussecukinumabarealworldefficacyandcostperrespondercomparisoninpatientswithpsoriasisinitaly AT robertoravasio risankizumabversussecukinumabarealworldefficacyandcostperrespondercomparisoninpatientswithpsoriasisinitaly AT antoniogiovannirichetta risankizumabversussecukinumabarealworldefficacyandcostperrespondercomparisoninpatientswithpsoriasisinitaly AT nevenaskroza risankizumabversussecukinumabarealworldefficacyandcostperrespondercomparisoninpatientswithpsoriasisinitaly AT marinatalamonti risankizumabversussecukinumabarealworldefficacyandcostperrespondercomparisoninpatientswithpsoriasisinitaly AT ariannazangrilli risankizumabversussecukinumabarealworldefficacyandcostperrespondercomparisoninpatientswithpsoriasisinitaly AT lucabianchi risankizumabversussecukinumabarealworldefficacyandcostperrespondercomparisoninpatientswithpsoriasisinitaly AT giovannipellacani risankizumabversussecukinumabarealworldefficacyandcostperrespondercomparisoninpatientswithpsoriasisinitaly AT severinopersechino risankizumabversussecukinumabarealworldefficacyandcostperrespondercomparisoninpatientswithpsoriasisinitaly AT concettapotenza risankizumabversussecukinumabarealworldefficacyandcostperrespondercomparisoninpatientswithpsoriasisinitaly AT kettyperis risankizumabversussecukinumabarealworldefficacyandcostperrespondercomparisoninpatientswithpsoriasisinitaly AT claradesimone risankizumabversussecukinumabarealworldefficacyandcostperrespondercomparisoninpatientswithpsoriasisinitaly |